SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin’s subsidiary receives green signal for anti-AIDS generic drug

16 May 2012 Evaluate

Pharma major, Lupin’s subsidiary, Lupin Pharmaceuticals Inc has received final approval for its Lamivudine and Zidovudine Tablets, 150 mg/300 mg from the United States Food and Drugs Administration (FDA). Lupin has already commenced shipping the product.

Lupin’s Lamivudine and Zidovudine Tablets are the AB rated generic equivalent of Viiv Healthcare’s Combivir  Tablets, 150/300 mg. Combivir Tablets, had annual US sales of approximately $27.5 crore for the twelve months ending December 2011 (IMS Health Sales Data).

Lamivudine Zidovudine is a combination of two nucleoside analogue reverse transcriplase inhibitors and is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

Lupin Share Price

2311.75 -16.85 (-0.72%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×